The short version of WADA fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
On 5 April 2024, the Mexican embassy in Quito was raided by Ecuadorian police and military forces. Mexico and numerous other countries decried the raid as a violation of the 1961 Vienna Convention on Diplomatic Relations and the 1954 Caracas Convention on Diplomatic Asylum. The raid was carried out to arrest the former vice president of Ecuador, Jorge Glas, who had been sentenced for corruption and had been living in the embassy since 17 December 2023. A few hours before the attack, he had been granted political asylum. In response to the raid, Noboa said he made "exceptional decisions to protect national security, the rule of law and the dignity of a population that rejects any type of impunity for criminals, corrupt people or narco-terrorists", and that he would "not allow sentenced criminals involved in very serious crimes to be given asylum", arguing that such actions were against the Vienna Convention and other international agreements. Noboa later said that he wished to resolve the diplomatic issue with Mexico, but added that "justice is not negotiated" and that "we will never protect criminals who have harmed Mexicans".
== History of profession == The idea of physician extenders was conceived in 1966 by physician-educator Eugene A. Stead at Duke University, where the first physician assistant program was established. Three years later, also at Duke, Chairman of Pathology, Dr. Thomas Kinney established the first pathologists’ assistant program. As of June 2025, seventeen accredited programs have been established across the United States and Canada and six others are in various stages of accreditation.
==== Selective serotonin reuptake inhibitors (SSRIs) ==== Escitalopram (Cipralex; Entact; Lexapro; LU-26054; MLD-55; (S)-citalopram; Seroplex; Sipralex; Sipralexa) – selective serotonin reuptake inhibitor (SSRI) [37] Paroxetine (Aropax; BRL-29060; Deroxat; Divarius; FG-7051; Frosinor; Motivan; NNC-207051; Paxil; Seroxat; SI-211103; Tagonis) – selective serotonin reuptake inhibitor (SSRI) [38] Paroxetine (Dropax; Dropaxin; Serestill) – selective serotonin reuptake inhibitor (SSRI) [39]
== Adverse effects == Cipaglucosidase alfa in combination with miglustat may cause serious side effects including life-threatening allergic reactions during and after the infusion and harm to an unborn baby if taken while pregnant. The most common side effects of cipaglucosidase alfa in combination with miglustat are headache, diarrhea, fatigue, nausea, abdominal pain, and fever.
Sources: en.wikipedia.org
In principle, mandating countries were only supposed to hold these former colonies "in trust" for their inhabitants, until they were sufficiently prepared for their own self-determination. Under these terms, Japan, Australia, and New Zealand were granted the German Pacific islands, and the Union of South Africa received South West Africa. It soon became apparent the South African government had interpreted the mandate as a veiled annexation. In September 1922, South African Prime Minister Jan Smuts testified before the League of Nations Mandate Commission that South West Africa was being fully incorporated into the Union and should be regarded, for all practical purposes, as a fifth province of South Africa. According to Smuts, this constituted "annexation in all but in name". Throughout the 1920s and 1930s, the League of Nations complained that of all the mandatory powers South Africa was the most delinquent with regards to observing the terms of its mandate. The Mandate Commission vetoed a number of ambitious South African policy decisions, such as proposals to nationalise South West African railways or alter the preexisting borders. Sharp criticism was also leveled at South Africa's disproportionate spending on the local white population, which the former defended as obligatory since white South West Africans were taxed the heaviest.
Finally, Marshall and coworkers found that P-selectin:PSGL-1 bonds exhibited increasing bond lifetime as step loads were applied between 0 and ~10 pN for monomeric interaction but 1 and ~20 pN for dimeric interaction, exhibiting catch bond behavior; after reaching maximum values, which were ~0.6 and 1.2 seconds for monomeric and dimeric interaction, respectively, the bond lifetime fell rapidly at higher loads, displaying slip bond behavior ("catch-slip" bonds). These data were collected using an atomic force microscope and a flow chamber, and have subsequently been duplicated using a biomembrane force probe. These finding prompted the discoveries of other important catch bonds in the 2000s, including those between L-selectin and PSGL-1 or endoglycan, FimH and mannose, myosin and actin, platelet glycoprotein Ib and von Willebrand factor, and integrin alpha 5 beta 1 and fibronectin. Emphasizing their importance and general acceptance, in the three years following their discovery there were at least 24 articles published on catch bonds. More catch bonds were discovered in the 2010s, including E-selectin with carbohydrate ligands, G-actin with G-actin or F-actin, cadherin-catenin complex with actin, vinculin with F-actin, microtubule with kinetochore particle, integrin alpha L beta 2 and intercellular adhesion molecule 1 (ICAM-1), integrin alpha 4 beta 1 with vascular adhesion molecule 1, integrin alpha M beta 2 with ICAM-1, integrin alpha V beta 3 with fibronectin, and integrin alpha IIb beta 3 with fibronectin or fibrinogen.
==== Extracellular phenoloxidases ==== Phenols are an important group of ecotoxins due to their toxicity and persistence. Many microorganisms can degrade aromatic pollutants and use them as a source of energy, and the ability of microalgae to degrade a multitude of aromatic compounds including phenolic compounds is increasingly recognized. Some microalgae including Chlamydomonas sp., Chlorella sp., Scenedesmus sp. and Anabaena sp. are able to degrade various phenols such as pentachlorophenol, p-nitrophenol, and naphthalenesulfonic acids. Though the metabolic degradation pathways are not fully understood, enzymes including phenoloxidase laccase (EC 1.10.3.2) and laccase-like enzymes are involved in the oxidation of aromatic substrates. These exoenzymes can be potentially applied in the environmental degradation of phenolic pollutants.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.